酪胺酸激酶抑制剂市场－全球产业规模、份额、趋势、机会和预测，按类型、应用、地区和竞争格局划分，2020-2030年预测

全球酪胺酸激酶抑制剂市场规模预计将从2024年的520.7亿美元成长至2030年的830.9亿美元，复合年增长率（CAGR）为8.10%。酪胺酸激酶抑制剂（TKIs）是一类旨在选择性阻断酪胺酸激酶活性的药物。酪胺酸激酶是细胞讯号传导、生长和分裂的关键酶，其作用机转是抑制肿瘤增生。在全球范围内，癌症发生率的不断攀升是推动此类标靶疗法市场成长的主要因素，这迫切需要先进且有效的治疗方法。

主要市场驱动因素

全球癌症发生率的不断攀升是酪胺酸激酶抑制剂市场的主要驱动力。全球新增癌症病例的庞大数量，从根本上推动了对创新有效治疗策略的需求。

主要市场挑战

全球酪胺酸激酶抑制剂市场成长面临的一大挑战是这些先进疗法的高昂成本。高昂的治疗费用直接限制了病患的就医途径，尤其是在医疗系统预算紧张、公共报销政策严格的地区。

主要市场趋势

酪胺酸激酶抑制剂（TKI）联合疗法的日益普及标誌着治疗模式的重大转变，它不仅提高了疗效，也有助于应对癌症中复杂的抗药性机制。这一趋势是将酪胺酸激酶抑制剂与其他药物（例如化疗或免疫疗法）合併使用，以期获得较佳的患者疗效。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球酪胺酸激酶抑制剂市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（BCR-ABL酪胺酸激酶抑制剂、表皮生长因子受体（EGFR）酪胺酸激酶抑制剂、血管内皮生长因子受体（VEGFR）酪胺酸激酶抑制剂、其他）
  • 依申请类别（慢性骨髓性白血病(CML)、肺癌、乳癌、肾细胞癌、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美酪胺酸激酶抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲酪胺酸激酶抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区酪胺酸激酶抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲酪胺酸激酶抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美酪胺酸激酶抑制剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球酪胺酸激酶抑制剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International
• Bristol-Myers Squibb Company
• Eisai Co. Ltd
• F. Hoffmann-La Roche Ltd
• Johnson and Johnson
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company

第十六章：策略建议

第17章调查会社について・免责事项

The Global Tyrosine Kinase Inhibitors Market will grow from USD 52.07 Billion in 2024 to USD 83.09 Billion by 2030 at a 8.10% CAGR. Tyrosine Kinase Inhibitors, or TKIs, are a class of pharmaceutical drugs designed to selectively block the action of tyrosine kinases, enzymes crucial for cell signaling, growth, and division, thereby inhibiting tumor proliferation. The global market for these targeted therapies is primarily driven by the escalating prevalence of cancer worldwide, which necessitates advanced and effective treatment modalities.

Key Market Drivers

The escalating global cancer incidence represents a primary impetus for the Tyrosine Kinase Inhibitors market. The sheer volume of new cancer diagnoses worldwide inherently drives the demand for innovative and effective therapeutic strategies. As the global population ages and lifestyles evolve, the burden of cancer continues to grow, necessitating targeted treatments that offer improved efficacy and patient outcomes.

Key Market Challenges

A significant challenge impeding the growth of the Global Tyrosine Kinase Inhibitors Market is the substantial cost associated with these advanced therapies. High treatment expenses directly restrict patient access, particularly in regions where healthcare systems operate under tight budgetary constraints and public reimbursement policies are stringent. This financial barrier limits the number of patients who can initiate and sustain TKI treatments, irrespective of medical need. Consequently, reduced patient uptake translates into lower sales volumes and slower market penetration for manufacturers of these inhibitors.

Key Market Trends

The increasing adoption of TKI combination therapies represents a pivotal shift in treatment paradigms, enhancing therapeutic efficacy and addressing complex resistance mechanisms in cancer. This trend involves combining tyrosine kinase inhibitors with other agents, such as chemotherapy or immunotherapies, to achieve superior patient outcomes.

Key Market Players

• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International
• Bristol-Myers Squibb Company
• Eisai Co. Ltd
• F. Hoffmann-La Roche Ltd
• Johnson and Johnson
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company

Report Scope:

In this report, the Global Tyrosine Kinase Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tyrosine Kinase Inhibitors Market, By Type:

• BCR-ABL Tyrosine Kinase Inhibitor
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
• Other

Tyrosine Kinase Inhibitors Market, By Application:

• Chronic Myeloid Leukemia (CML)
• Lung Cancer
• Breast Cancer
• Renal Cell Cancer
• Other

Tyrosine Kinase Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tyrosine Kinase Inhibitors Market.

Available Customizations:

Global Tyrosine Kinase Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tyrosine Kinase Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other)
  • 5.2.2. By Application (Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Tyrosine Kinase Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tyrosine Kinase Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Tyrosine Kinase Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Tyrosine Kinase Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Tyrosine Kinase Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Tyrosine Kinase Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Tyrosine Kinase Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Tyrosine Kinase Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Tyrosine Kinase Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Tyrosine Kinase Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Tyrosine Kinase Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Tyrosine Kinase Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Tyrosine Kinase Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Tyrosine Kinase Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Tyrosine Kinase Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bayer AG
• 15.3. Boehringer Ingelheim International
• 15.4. Bristol-Myers Squibb Company
• 15.5. Eisai Co. Ltd
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Johnson and Johnson
• 15.8. Novartis AG
• 15.9. Pfizer Inc.
• 15.10. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer